Home / Awards / Citeline Pharma Intelligence Awards 2022
winners announced!
Citeline Pharma Intelligence Awards 2022
01 Sep 2022 - 23:30 - 00:00
Palace Hotel, Tokyo
Abstract blue and green spiral.

Sponsored By

About this award

 

The inaugural Informa Pharma Intelligence Awards recognize outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market.

Taking place on 1 September 2022, the Awards brought together leading innovators, to meet and network, discover new opportunities, and reflect on life-changing accomplishments made over the previous year.

Categories cover the entire pharma and biotech lifecycle, including: Pharma Company of the Year, Best New Drug Award, Executive of the Year, Biotech Company of the Year, Best Contract Research Organization, Licensing Deal of the Year and Lifetime Achievement Award.


Key details 

  Ceremony, Thursday, 01 September, 2022

  Palace Hotel, Tokyo

THE CITELINE PHARMA INTELLIGENCE AWARDS JAPAN CATEGORIES
WINNER

CMIC Group

 

FINALIST
  • Avance Clinical
  • Calyx
  • CMIC Group
  • EPS
  • ICON
  • Parexel
  • Syneos Health
WINNER

Daiichi Sankyo

 

FINALIST
  • Daiichi Sankyo
  • Shionogi
  • Takeda
WINNER

Fujifilm Toyama Chemical, Lutathera for neuroendocrine tumors

 

FINALISTS
  • Astellas’ Padcev (enfortumab vedotin) for urothelial carcinoma
  • Fujifilm Toyama Chemical’s Lutathera (lutetium oxodotreotide) for neuroendocrine tumors
  • JCR Pharma’s Izcargo (pabinafusp alfa) for mucopolysaccharidosis type II Otsuka Pharm’s Moizerto (difamilast) for atopic dermatitis
  • Sanwa Kagaku’s Upasita (upacicalcet sodium hydrate) for secondary hyperparathyroidism in hemodialysis patients
  • Takeda’s Alofisel (darvadstrocel) for complex perianal fistulas in Crohn’s disease
  • Takeda’s Revestive (teduglutide) for short bowel syndrome
WINNER

PRISM BioLab

 

FINALISTS
  • ARTham Therapeutics
  • Chordia Therapeutics
  • Cuorips
  • Heartseed
  • PRISM BioLab
  • Rebirthel
  • ReboRNA Biosciences
  • TMS
WINNER

Sosei Heptares with Neurocrine Biosciences for novel muscarinic receptor agonists 

 

FINALISTS
  • Asahi Kasei Pharma with Lilly for chronic pain candidate AK1780
  • Heartseed with Novo Nordisk for heart failure candidate HS-001
  • Rebirthel with Otsuka Pharmaceutical for iPSC-derived CAR-T/TCR-T therapies
  • ReboRNA Biosciences’ research collaboration/option deal with Biogen for CNS disorders
  • Sosei Heptares with Neurocrine Biosciences for novel muscarinic receptor agonists
WINNER

Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate)

 

FINALISTS
  • NanoCarrier
  • Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate)
  • Sosei Heptares
  • Stella Pharma
  • StemCell Institute
WINNER

Chris Cargill, executive officer, chief financial officer, Sosei Heptares

 

FINALISTS
  • Chris Cargill, executive officer, chief financial officer, Sosei Heptares (this relates to his position at the time of nomination)
  • Hiroshi Kawamoto, director, Rebirthel, and professor, Laboratory of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University
  • Tetsuhito Matsuyama, president and CEO, NanoCarrier
  • Daisuke Morishita, co-founder and chief scientific officer, Chordia Therapeutics
  • Kazuo Nakamura, chairman and CEO, CMIC Group

Dr. Toichi Takenaka

HEADLINE SPONSOR

ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.

 
OUR 2022 SPONSORS
CMIC
CMIC stands for Current Medical Information Center. In 1992, Dr. Kazuo Nakamura founded CMIC as the first Contract Research Organization (CRO) in Japan. CMIC Group is currently the largest clinical CRO in Japan, providing comprehensive services in drug development, clinical trial and clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge your drug development and manufacturing needs between the US and Japan. CMIC Group has over 7,000 employees and 25 sites globally.
Avance Clinical
Avance Clinical is a premium full-service Contract Research Organisation (CRO) based in Australia, New Zealand and North America, providing high-quality clinical research services to the international drug development industry which brings innovative new drugs to patients. Avance Clinical has more than 260 staff and has backing from the private equity group, Riverside Company, to support global expansion plans.

Avance Clinical offers clinical project management, trial monitoring, regulatory support, safety reporting, scientific and medical writing, data management, statistical and pharmacokinetic services, and external clinical auditing. We operate to the highest standards of compliance required by global regulatory agencies such as the FDA to ensure acceptance of data for drug approvals.

Our clients are international biotech companies in their early phases of drug development that require fast, agile, and adaptive solution-oriented clinical research services. The company uses state-of-the-art technology, gold standard systems, and deep scientific expertise to provide clients with the most successful outcomes.

The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.
Want to sponsor an award
Awards Judges
Headshot of Fumiyoshi Sakai.
Fumiyoshi Sakai
Japan Healthcare Strategist, Global Research Division
UBS Securities Japan Co., Ltd.
''
Dr Noboru Yamamoto
Deputy Director, Director / Clinical Research Support Office, Director
National Cancer Center Hospital, Department of Experimental Therapeutics
''
Dr Shingo Kano
Professor
University of Tokyo/Graduate School of Frontier Sciences
Photo of Steve Engen.
Steve Engen
CEO
Renexes LLC, ex-President, Mundipharma Japan and Solasia Pharma
''
Shoichiro Hamano
CEO
Hamano International
''
Mitsuru Miyata
CEO
Miyata Institute of Technologies/President, Healthcare Innovation
''
Thomas Jonsson
Managing Director
Zinagi Consulting
''
Koji Kawakami
Professor
Graduate School of Medicine, Kyoto University
''
Dr Yujiro Maeda
Director, Co-founder ,Director, Co-founder and Chairman, Global Faculty, Co-Director, Specially Appointed Professor, Visiting Lecturer
Department of Biodesign, The University of Tokyo Hospital , Premo Partner Inc, Aillis Inc. , Kozue Medical Group , Stanford Biodesign,Japan Biodesign , Tokyo University of Pharmacy and Life Sciences , Waseda University Business School
Fumiyoshi Sakai
Japan Healthcare Strategist, Global Research Division
 UBS Securities Japan Co., Ltd.
After graduating from Arizona State University with a degree in Finance, Mr. Sakai joined Imperial Chemical Industries Japan, a British chemical company, where he worked for five years in Japan and the UK. Mr. Sakai then joined the Corporate Research Department of the Economic Research Institute of Yamaichi Securities. After this, Mr. Sakai joined Société Générale, working within Domestic Equities and the Corporate Research Department in 1998. Since 2002, he has worked as an analyst for the pharmaceutical industry in Deutsche Securities' Equities Research Department. Mr. Sakai joined Credit Suisse First Boston Securities (now Credit Suisse Securities (Japan) Limited) in July 2005 where he worked as a Senior Analyst and Director in the Equity Research Department. In both 2008 and 2009, Mr. Sakai was ranked third in the pharmaceutical sector by Institutional Investor magazine. He is a member of the Securities Analysis Association of Japan. He is also the author of several books.
Dr Noboru Yamamoto
Deputy Director, Director / Clinical Research Support Office, Director
 National Cancer Center Hospital, Department of Experimental Therapeutics
Dr. Yamamoto graduated from Hiroshima University School of Medicine in 1991 and started his residency in internal medicine at the National Cancer Center Hospital in 1995. Dr. Yamamoto became a physician in the Department of Respiratory Medicine at the National Cancer Center Hospital in 2000, and in 2013 he progressed to Director of the Department of Advanced Medicine there. Since 2019, Dr Yamamoto has worked as the Director of the Division of Clinical Research Support and Deputy Director of the National Cancer Center Hospital. Dr Yamamoto specializes in the early clinical development of novel anticancer agents, thoracic oncology and clinical pharmacology. Dr. Yamamoto received the ASCO Merit Award in 1996, 1999 and 2000, and has been a member of the editorial board of the Japanese Journal of Clinical Oncology since 2005.
Dr Shingo Kano
Professor
 University of Tokyo/Graduate School of Frontier Sciences
Shingo Kano is a Professor in Bio-Innovation Policy Unit, Graduate school of Frontier Science, the University of Tokyo, where he also completed his PhD in Science Policy. He had a varied career in industry as management consultant in Nomura Research Institute, securities analyst and venture capitalist for the healthcare sector in Nomura Securities and run the university spin off drug discovery firm as president and CEO for ten years before starting his academic career.
His current research focuses on the recognition gap between university and industry, the role and management of university spin off, how regulation and innovation interact in the advanced industries, and the changing role of universities and companies in the national innovation systems.
Steve Engen
CEO
  Renexes LLC, ex-President, Mundipharma Japan and Solasia Pharma
Steve brings over 20 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets. In 2014, he established his own biopharma consultancy, and continues to support Japanese, Chinese, and western biopharma clients. From 2014 until May 2018, Steve was Managing Director and Head of Asia for Locust Walk, where he established the Locust Walk Japan office. During the four years that Steve ran the Locust Walk Japan office, he oversaw eleven transactions (including buy-side and sell-side transactions) between western and Asian companies.
Steve previously headed the Japanese operations of Shire Pharmaceuticals. Before Shire, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company. Raising over $40MM in venture capital, he built a portfolio of novel cancer drugs and established operations in Japan and China. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Mundipharma Japan for nine years. In this role, he oversaw the development and commercialization of the company’s leading pain management franchise.
Steve, his wife, and two daughters currently have their primary residence in Bellevue, Washington. Steve is fluent in written and spoken Japanese.
Shoichiro Hamano
CEO
 Hamano International
He is a recipient of the U.S. FDA Commissioner's Special Award and a former ICHGMP EWG member and received his PhD from the University of Tokyo and his Master's degree from Kanazawa University, in pharmacy, a registered Pharmacist, involved in new business development, technology transfer, licensing, negotiation, contract drafting, JV establishment, and M&A for 25 years in big pharma.
His areas of expertise include licensing, technology transfer, new business development, start-up consulting and related services, currently serves as an adviser to the Toyama Pharmaceutical Association. He also served as the Senior Vice President of KUTLO-NITT (TLO Union), as CD of Hokuriku Innovation Cluster for Health Science and adviser to the DBJ VC "BHP".
He has visited more than 250 venture companies in the world and made business contacts with more than 350 leading pharmaceutical companies in Japan and overseas. Traveled overseas more than 300 times.
Office is located in Nihonbashi, Tokyo, the center of Japan's pharmaceutical industry.
Mitsuru Miyata
CEO
 Miyata Institute of Technologies/President, Healthcare Innovation
Mr. Miyata joined Nikkei Inc. in 1979 after completing a postgraduate degree in Botany at the University of Tokyo. Mr. Miyata then worked in the editorial department of Nikkei medical and was involved in the launch of Nikkei biotech. Mr. Miyata was then appointed as the Editor-in-Chief of Nikkei biotech in 1985. In July 2015, Mr. Miyata founded the Miyata Institute of Technologies and became the President. Then in April 2017, he founded Healthcare Innovation and was appointed it’s President.
He is also involved in various public activities such as being the Ministry of Health, Labour and Welfare and AMED.
Thomas Jonsson
Managing Director
 Zinagi Consulting
Thomas established Zinagi, a lifescience consulting company, in 2013 and has successfully supported innovative medical device, medical software, and biotech companies. Thomas previously served as Lifescience Ambassador for Medicon Valley Alliance and prior to that held commercial positions at several global big pharma companies.
Koji Kawakami
Professor
 Graduate School of Medicine, Kyoto University
Graduated from the University of Tsukuba School of Medicine (doctor's license) in 1997, and graduated from Yokohama City University Graduate School of Medicine (Doctor of Medicine) in 2001. He has served as a clinical trial examiner and researcher in the Department of Cell Gene Therapy at the US Federal Food and Drug Administration (FDA) Biopharmaceutical Evaluation and Research Center (CBER), and is engaged in clinical trial review work and administrative guidance in the United States. After working as a visiting assistant professor at the Graduate School of Medicine, the University of Tokyo, he became a professor at Kyoto University at the age of 33 in 2006 (Graduate School of Medicine, Department of Social Health Medicine, Drug Epidemiology). 2010-2014 Assistant Director of Kyoto University (Research), 2011 Director of Science Unit for Interdisciplinary Education and Research Promotion Center, Kyoto University. He also serves as a visiting professor at Keio University School of Medicine. There are more than 160 original papers.
Dr Yujiro Maeda
Director, Co-founder ,Director, Co-founder and Chairman, Global Faculty, Co-Director, Specially Appointed Professor, Visiting Lecturer
 Department of Biodesign, The University of Tokyo Hospital , Premo Partner Inc, Aillis Inc. , Kozue Medical Group , Stanford Biodesign,Japan Biodesign , Tokyo University of Pharmacy and Life Sciences , Waseda University Business School
Yujiro has promoted the development of medical technology that starts from the needs of the medical field.
He completed doctor course in Medicine from the University of Tokyo Graduate School of Medicine & School of Dentistry in Kyushu University. He engaged in clinical practice at the University of Tokyo Hospital, Department of Oral and Maxillofacial Surgery, Department of Orthodontics, and Emergency Department. In 2013, he was engaged in tele-health business in the Pharmaceutical Business Planning Department of Otsuka Pharmaceutical Co.
In June 2014, he completed the Global Faculty training program at Stanford University's Biodesign Program, a program to develop innovators for medical device invention and entrepreneurship. In 2015, he founded Japan Biodesign and started 0→1 acceleration of medical deep technology startups. Since then, he has been co-director of Japan Biodesign. In the same year,he was assigned to be a global member of SPARK, Stanford University's translational program for drug discovery and biotechnology. In 2020, he became the Director of the Department of Biodesign, Translational Research Center, University of Tokyo Hospital.
In 2018, he became a director of Aillis Inc., a medical AI startup, and in 2019, he co-founded Premo Partner Inc. and started advising major manufacturers on new business, incubating medical startups, and angel investing.
He is also a Specially Appointed professor at Tokyo University of Pharmacy and Life Sciences (2020-), a visiting lecturer at Waseda University Business School (2018-), Advisor to Eten Lab Inc. which provides "Minchare", a program to change society through behavioral change (2016-). Co-Founder of Vice-Director of Kozue Medical Corporation(2019-).
Next Steps
Sponsorship Opportunities
Sponsorship provides a wealth of opportunities, from thought leadership to brand awareness and lead generation. Find out more about the numerous sponsorship opportunities available.